Figure 5 from Estrogen Receptor Blockade Potentiates Immunotherapy for Liver Metastases by Altering the Liver Immunosuppressive Microenvironment

Fulv reprograms the liver TME and inhibits CRCLM outgrowth. Experimental LM were generated by intrasplenic/portal injection of 10⁵ MC-38 cells. Mice received eight subcutaneous injections of Fulv or vehicle on alternate days and were sacrificed 21 days post tumor inoculation. Results shown are of a representative experiment of two performed. In A are metastases counted per liver (n = 5–6), in B mean nodule size (mm; n = 5–6), and in C representative liver images. Hepatic immune cells were isolated in a separate experiment 7 days post-injection, stained with the indicated antibodies, and analyzed by FC. Shown in D (left) are representative FC contour plots (n = 3–4) and in D (right) cell counts (means ± SD). *, P ≤ 0.05, Mann–Whitney test (metastases) or Student t test (FC).